Biotech Stocks To Consider – February 02nd

AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks refer to stocks of companies that are primarily involved in the research, development, and commercialization of biological products or technologies, such as genetic engineering, drug development, and biopharmaceuticals. These stocks are typically in the healthcare or pharmaceutical sectors and are often known for their potential for high growth and volatility due to the uncertainty of clinical trial outcomes and regulatory approvals. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE ABBV traded up $8.25 during mid-day trading on Friday, reaching $183.90. 11,926,469 shares of the company’s stock were exchanged, compared to its average volume of 5,362,292. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. AbbVie has a 52 week low of $153.58 and a 52 week high of $207.32. The firm has a 50-day moving average price of $176.57 and a two-hundred day moving average price of $185.06. The firm has a market capitalization of $324.98 billion, a price-to-earnings ratio of 63.85, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Vertex Pharmaceuticals stock traded up $23.28 during trading on Friday, reaching $461.68. The company had a trading volume of 3,646,769 shares, compared to its average volume of 1,346,207. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $434.55 and its 200 day simple moving average is $462.93. The firm has a market capitalization of $118.90 billion, a price-to-earnings ratio of -232.00, a price-to-earnings-growth ratio of 2.29 and a beta of 0.40.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of NYSE TMO traded down $8.34 during trading on Friday, reaching $598.40. The stock had a trading volume of 2,165,717 shares, compared to its average volume of 1,840,120. Thermo Fisher Scientific has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The business’s 50-day moving average price is $541.37 and its 200-day moving average price is $571.07. The company has a market cap of $228.89 billion, a P/E ratio of 37.52, a PEG ratio of 3.89 and a beta of 0.76.